UNIVERSITY OF CALIFORNIA, LOS ANGELES
Total received in grants · trailing 12 months
$5.6M
$0for every U.S. household÷ 131M U.S. households
In perspective
0.0%of all $162.9B in tracked grants
3separate grants, trailing 12 months
UNIVERSITY OF CALIFORNIA, LOS ANGELES has received $5.6M across 3 federal grants of $1M or more on record.
Data as of July 24, 2026. Source: USAspending.gov, prime contract awards $1M+. Federal spending data lags and has known gaps. This is not a real-time or complete record.
Grants by agency
Where this recipient’s grant dollars come from.
All grant awards
Swipe to see description and amount →
| Agency | Description | Amount |
|---|---|---|
| Department of Energy | TARGETED EXTRACTION OF VALUABLE INTERMEDIATE PRODUCTS AND CLEAN WATER FROM MUNICIPAL WASTEWATER USING ELECTROACTIVE ANAEROBIC MEMBRANE BIOREACTORS (ANEMBR) | $1,999,841 |
| Department of Health and Human Services | CRYOFIB INSTRUMENT FOR BIOMEDICAL CRYOEM/ET LAMELLAE PREPARATION - SUMMARY THE CALIFORNIA NANOSYSTEMS INSTITUTE (CNSI) AT THE UNIVERSITY OF CALIFORNIA, LOS ANGELES (UCLA), IS COMMITTED TO PIONEERING NANOBIOLOGY AND BIOMEDICAL RESEARCH. CENTRAL TO THIS MISSION, THE ELECTRON IMAGING CENTER FOR NANOSYSTEMS (EICN), ESTABLISHED IN 2007, PROVIDES CUTTING-EDGE CRYOGENIC ELECTRON MICROSCOPY (CRYOEM) INSTRUMENTS AND SPECIALIZED EXPERTISE TO ELUCIDATE THE MECHANISMS OF MOLECULAR MACHINERY AT THE NANOMETER SCALE. A PREVIOUS NIH S10 AWARD WAS PIVOTAL IN INSTALLING THE WORLD’S FIRST OPERATIONAL TITAN KRIOS IN 2008, A LANDMARK ACHIEVEMENT THAT FUELED THE CRYOEM REVOLUTION OF THE PAST DECADE. THIS INSTRUMENT PRODUCED DATA FOR ONE OF THE EARLIEST NEAR-ATOMIC-RESOLUTION SINGLE-PARTICLE CRYOEM STRUCTURES AND PLAYED A CRITICAL ROLE IN MODERNA’S GROUNDBREAKING MRNA VACCINE DEVELOPMENT. BUILDING ON THIS SUCCESS, A SECOND NIH S10 AWARD ENABLED THE ACQUISITION OF A TITAN KRIOS G4 IN 2024, EQUIPPED WITH ADVANCED TECHNOLOGIES FOR BOTH CRYOEM IMAGING AND CRYOGENIC ELECTRON TOMOGRAPHY (CRYOET) TILT SERIES ACQUISITION. THESE STATE-OF-THE-ART INSTRUMENTS SUPPORT HUNDREDS OF REGISTERED UCLA USERS, FACILITATING ATOMIC-LEVEL STRUCTURAL ANALYSIS OF ISOLATED OR ENRICHED BIOLOGICAL COMPLEXES FOR A WIDE RANGE OF RESEARCH APPLICATIONS. WHILE EICN’S CRYOEM AND CRYOET CAPABILITIES MEET CURRENT USER NEEDS, THE LACK OF A CRYOGENIC FOCUSED ION BEAM (CRYOFIB) INSTRUMENT SIGNIFICANTLY RESTRICTS OUR LARGE USER BASE FROM CONDUCTING IN SITU STRUCTURAL STUDIES WITHIN CELLS AND TISSUES USING CRYOET. MOST CELLS, EXCEEDING 1 ΜM IN THICKNESS, ARE TOO DENSE FOR ELECTRON PENETRATION AND REQUIRE PRECISE MILLING INTO LAMELLAE OF 200 NM OR LESS TO ENABLE HIGH-RESOLUTION CRYOEM OR CRYOET IMAGING. THIS APPLICATION SEEKS FUNDING TO ACQUIRE AN AQUILOS 2 CRYOFIB INSTRUMENT, WHICH WILL EMPOWER NIH-SUPPORTED BIOMEDICAL RESEARCH ACROSS 38 USER LABORATORIES (INCLUDING 26 MAJOR USERS) WITHIN EICN’S EXTENSIVE USER COMMUNITY. THE PROPOSED CRYOFIB WILL SUBSTANTIALLY ENHANCE EICN’S CELLULAR CRYOET CAPABILITIES, ADVANCING FEDERALLY FUNDED RESEARCH IN CRITICAL AREAS SUCH AS VIRAL AND MICROBIAL INFECTIONS, NEURODEGENERATIVE DISORDERS, TUMORIGENESIS, THERAPEUTIC DEVELOPMENT, DRUG DESIGN, AND VACCINE DELIVERY SYSTEMS, AS WELL AS THE PI CONTINUOUS CRYOEM/CRYOET METHOD DEVELOPMENT. THE AQUILOS 2 CRYOFIB WILL BENEFIT FROM ROBUST INSTITUTIONAL SUPPORT, INCLUDING DEDICATED STAFF, ONGOING INSTRUMENT MAINTENANCE, AND OPERATIONAL RESOURCES, ENSURING LONG-TERM IMPACT AND ACCESSIBILITY. THE INSTRUMENT WILL BE MANAGED BY EICN’S HIGHLY EXPERIENCED CORE FACILITY TEAM, WHICH HAS SUCCESSFULLY OPERATED THE FACILITY FOR 18 YEARS SINCE ITS INCEPTION. THE PRINCIPAL INVESTIGATOR, MANAGING DIRECTOR, FACILITY TECHNICIAN, AND USER COORDINATOR POSSESS THE TECHNICAL EXPERTISE AND OPERATIONAL EXPERIENCE NECESSARY TO ENSURE THE CRYOFIB’S SEAMLESS INTEGRATION AND PRODUCTIVE USE. THIS HIGH-END S10 INSTRUMENT WILL IMMEDIATELY BOLSTER NIH- FUNDED BIOMEDICAL RESEARCH ACROSS UCLA’S COLLEGES OF NATURAL SCIENCES, ENGINEERING, AND THE DAVID GEFFEN SCHOOL OF MEDICINE, DRIVING TRANSFORMATIVE DISCOVERIES IN STRUCTURAL BIOLOGY AND BEYOND. | $1,995,285 |
| Department of Health and Human Services | NIDDK HERITAGE: HARNESSING TANDEM REPEATS IN MULTI-ANCESTRY METABOLIC GENE-PHENOTYPE RELATIONSHIPS - PROJECT SUMMARY DIABETES AND OBESITY ARE TWO OF THE MOST PREVALENT AND FASTEST GROWING METABOLIC DISORDERS. BOTH ARE HEAVILY INFLUENCED BY GENETIC FACTORS, WITH HERITABILITY ESTIMATES REACHING UP TO 80%. GENOME-WIDE ASSOCIATION STUDIES (GWAS) AND TARGET SEQUENCING EFFORTS HAVE IDENTIFIED THOUSANDS OF SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS), INCLUDING RARE VARIANTS, BUT THESE COLLECTIVELY ACCOUNT FOR A SMALL FRACTION OF THE HERITABILITY. THUS, A SIGNIFICANT PORTION OF THE GENETIC INFLUENCE ON DIABETES AND OBESITY REMAINS UNEXPLAINED, HINDERING EFFORTS TO DEVELOP EFFECTIVE PREVENTION AND TREATMENT STRATEGIES. FURTHERMORE, METABOLIC TRAITS AND THEIR COMPLICATIONS VARY BY ANCESTRAL BACKGROUND, YET WE HAVE LIMITED UNDERSTANDING OF THE GENETIC CONTRIBUTORS TO THE HETEROGENEITY OF DIABETES AND OBESITY. CAPITALIZING ON RESEARCH INVESTMENTS AND UNIQUE EXPERTISE, OUR GROUP HAS UNRAVELED A NEW CODE IN METABOLIC GENE-PHENOTYPE RELATIONSHIPS. WE FOUND THAT VARIATION IN NUMBER OF DNA TANDEM REPEATS (E.G., 10 VS. 15 CAG REPEATS) IS A SIGNIFICANT CONTRIBUTOR TO GENETIC HETEROGENEITY AND UNDERLIES MANY PREVIOUSLY UNRECOGNIZED DISEASES, INCLUDING COMPLEX POLYGENIC TRAITS. ALIGNED WITH THE MISSION OF NIH AND THE GOALS OF THE RC2 MECHANISM, WE FOUNDED THE HERITAGE STUDY TO DEVELOP TANDEM REPEAT (TR) RESOURCES THAT WILL ENHANCE OUR UNDERSTANDING OF THE GENETIC ARCHITECTURE OF DIABETES AND OBESITY. IN AIM 1, WE LEVERAGE EXISTING WHOLE-GENOME SEQUENCING (WGS) DATA FROM DIABETES AND OBESITY COHORTS TO ESTABLISH A TR ATLAS AND PERFORM TR-GWAS TO IDENTIFY NEW GENETIC CONTRIBUTORS. AIM 2, FOCUSES ON USING INNOVATIVE COMPUTATIONAL TOOLS TO REVEAL THE MOLECULAR MECHANISMS THROUGH WHICH TRS IMPACT DIABETES AND OBESITY AND VALIDATE CAUSAL EFFECTS OF TRS. BY COMBINING EXPERTISE IN BASIC METABOLIC BIOLOGY, BIOINFORMATICS, AND POPULATION GENETICS, OUR TEAM WILL DEVELOP A COMPREHENSIVE TR RESOURCE TO ADVANCE KNOWLEDGE OF THE GENETICS OF DIABETES AND OBESITY. | $1,581,254 |